Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

Article Cardiac & Cardiovascular Systems

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Javed Butler et al.

Summary: This study evaluated the impact of Empagliflozin on health-related quality of life in patients with heart failure and preserved ejection fraction. The results showed that Empagliflozin reduced the risk of major heart failure outcomes and improved health-related quality of life. The effects were consistent across different levels of baseline health status.

CIRCULATION (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Javed Butler et al.

Summary: This secondary analysis of the EMPEROR-Reduced trial found that empagliflozin improved the risk of cardiovascular death or heart failure hospitalization across a range of baseline health statuses. The benefits of empagliflozin in improving health status were sustained during long-term follow-up.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

Jasper Tromp et al.

Summary: The EMPULSE trial aims to assess the clinical benefits and safety of the SGLT2 inhibitor empagliflozin compared to placebo in patients hospitalized for AHF. Approximately 500 patients across North America, Europe, and Asia will be randomized to receive either empagliflozin or placebo, with the primary outcome being clinical benefit at 90 days. Secondary outcomes include safety assessments and changes in symptom scores and natriuretic peptides.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif et al.

Summary: In a randomized trial, the SGLT2 inhibitor dapagliflozin significantly improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF) over a 12-week period, which can lead to an enhanced quality of life for these patients.

NATURE MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure

Maria Belkin et al.

Summary: The study aimed to assess the long-term effect of comprehensive vasodilation strategy versus usual care on health-related quality of life among patients with acute heart failure. Results showed significant improvements in HRQL quantified by EQ-5D and KCCQ within 180 days of follow-up, with no significant differences between the two treatment strategies.

ESC HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Ewa A. Jankowska et al.

Summary: Patients with heart failure and iron deficiency experience poor health-related quality of life. Treatment with intravenous ferric carboxymaltose results in clinically beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to 24 weeks.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Ewa A. Jankowska et al.

Summary: The study showed that in iron-deficient patients who had stabilized after an episode of acute heart failure, treatment with IV FCM resulted in significant beneficial effects on HRQoL, lasting up to 24 weeks.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems